Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT with vs without curettage for actinic keratosis
NCT03697590Phase 4Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jun 2017
- Primary completion
- Dec 2017
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Complete lesion response rate at 3 months. Started Jun 2017; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03697590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697590.